Quest Diagnostics Inc. DGX
Price
Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)
Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.
Results from SEC filings
| Revenue | $11.0B | +12% | FY ending Dec 31, 2025 |
|---|---|---|---|
| Gross profit | $3.6B | +35% | FY ending Dec 31, 2020 |
| Operating income | $1.6B | +16% | FY ending Dec 31, 2025 |
| Net income | $992.0M | +14% | FY ending Dec 31, 2025 |
| Earnings per share | $8.75 | +14% | FY ending Dec 31, 2025 |
| Cash from operations | $1.9B | +41% | FY ending Dec 31, 2025 |
| Capital spending | $527.0M | +24% | FY ending Dec 31, 2025 |
| Share buybacks | $450.0M | +198% | FY ending Dec 31, 2025 |
| Dividends paid | $353.0M | +7% | FY ending Dec 31, 2025 |
| Cash | $420.0M | -23% | FY ending Dec 31, 2025 |
| Long-term debt | $5.2B | -8% | FY ending Dec 31, 2025 |
| Shareholders' equity | $7.2B | +6% | FY ending Dec 31, 2025 |
Insider trades
Last 12 months: 0 open-market buys ($0) and 22 sales ($37.3M) by officers, directors and big owners. These are exact: shares times the price each insider reported. Several sales by one person on one day are combined (average price).
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gary M PfeifferDirector | Soldpre-set plan | 1,203 | $243.00 | $292K | Oct 26, 2026 |
| J. E. DavisCEO and President, Director | Soldpre-set plan | 10,000 | $242.72 | $2.4M | Sep 1, 2026 |
| Michael E PrevoznikSVP & General Counsel | Soldpre-set plan3 fills | 22,677 | $243.11 avg | $5.5M | Aug 28, 2026 |
| Mark E DelaneySVP & Chief Commercial Officer | Soldpre-set plan | 1,600 | $235.18 | $376K | Jul 28, 2026 |
| Karthik KuppusamySVP, Clinical Solutions | Soldpre-set plan | 8,147 | $200.00 | $1.6M | Jun 4, 2026 |
| J. E. DavisCEO and President, Director | Soldpre-set plan | 10,000 | $194.14 | $1.9M | Jun 1, 2026 |
| Catherine T. DohertyEVP, Regional Businesses | Soldpre-set plan | 5,558 | $206.21 | $1.1M | Mar 5, 2026 |
| Michael E PrevoznikSVP & General Counsel | Soldpre-set plan | 3,878 | $206.21 | $800K | Mar 5, 2026 |
| Patrick PlewmanSVP for Diagnostic Services | Soldpre-set plan | 2,855 | $206.21 | $589K | Mar 5, 2026 |
| Karthik KuppusamySVP, Clinical Solutions | Sold | 2,628 | $204.86 | $538K | Mar 4, 2026 |
| Catherine T. DohertyEVP, Regional Businesses | Soldpre-set plan | 632 | $207.73 | $131K | Mar 3, 2026 |
| Michael E PrevoznikSVP & General Counsel | Soldpre-set plan | 526 | $207.73 | $109K | Mar 3, 2026 |
| Patrick PlewmanSVP for Diagnostic Services | Soldpre-set plan | 410 | $207.73 | $85K | Mar 3, 2026 |
| J. E. DavisCEO and President, Director | Soldpre-set plan | 10,000 | $212.52 | $2.1M | Mar 2, 2026 |
| Catherine T. DohertyEVP, Regional Businesses | Soldpre-set plan | 1,433 | $204.83 | $294K | Feb 19, 2026 |
| Michael E PrevoznikSVP & General Counsel | Soldpre-set plan | 1,111 | $204.83 | $228K | Feb 19, 2026 |
| Patrick PlewmanSVP for Diagnostic Services | Soldpre-set plan | 958 | $204.83 | $196K | Feb 19, 2026 |
| Catherine T. DohertyEVP, Regional Businesses | Soldpre-set plan5 fills | 26,165 | $206.15 avg | $5.4M | Feb 13, 2026 |
| Patrick PlewmanSVP for Diagnostic Services | Soldpre-set plan | 5,662 | $204.00 | $1.2M | Feb 10, 2026 |
| J. E. DavisCEO and President, Director | Soldpre-set plan3 fills | 55,093 | $192.22 avg | $10.6M | Nov 25, 2025 |
| Vicky B GreggDirector | Sold | 1,250 | $191.76 | $240K | Nov 25, 2025 |
| Mark E DelaneySVP & Chief Commercial Officer | Soldpre-set plan | 7,946 | $187.35 | $1.5M | Nov 18, 2025 |
Other insider moves (88): pay awards, option exercises, tax withholding, gifts
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sam SamadExecutive Vice President & CFO | Award | 90 | $235.94 | $21K | Oct 21, 2026 |
| Vicky B GreggDirector | Award | 63 | $235.94 | $15K | Oct 21, 2026 |
| Patrick PlewmanSVP for Diagnostic Services | L | 41 | $235.94 | $9,674 | Oct 21, 2026 |
| Karthik KuppusamySVP, Clinical Solutions | L | 33 | $235.94 | $7,786 | Oct 21, 2026 |
| Mark E DelaneySVP & Chief Commercial Officer | L | 25 | $235.94 | $5,899 | Oct 21, 2026 |
| Timothy L MainDirector | L | 18 | $235.94 | $4,247 | Oct 21, 2026 |
| Robert B CarterDirector | L | 10 | $235.93 | $2,359 | Oct 21, 2026 |
| Wright Iii LassiterDirector | L | 6 | $235.96 | $1,416 | Oct 21, 2026 |
| Michael E PrevoznikSVP & General Counsel | Option exercisepre-set plan | 22,677 | $112.17 | $2.5M | Aug 28, 2026 |
| Michael E PrevoznikSVP & General Counsel | Giftpre-set plan | 1,000 | – | – | Aug 28, 2026 |
| Sam SamadExecutive Vice President & CFO | Award | 102 | $206.81 | $21K | Jul 22, 2026 |
| Vicky B GreggDirector | Award | 72 | $206.81 | $15K | Jul 22, 2026 |
| Patrick PlewmanSVP for Diagnostic Services | L | 46 | $206.81 | $9,513 | Jul 22, 2026 |
| Karthik KuppusamySVP, Clinical Solutions | L | 37 | $206.81 | $7,652 | Jul 22, 2026 |
| Mark E DelaneySVP & Chief Commercial Officer | L | 34 | $206.81 | $7,031 | Jul 22, 2026 |
| Timothy L MainDirector | L | 21 | $206.81 | $4,343 | Jul 22, 2026 |
| Robert B CarterDirector | L | 11 | $206.80 | $2,275 | Jul 22, 2026 |
| Wright Iii LassiterDirector | L | 6 | $206.81 | $1,241 | Jul 22, 2026 |
| Karthik KuppusamySVP, Clinical Solutions | Option exercisepre-set plan2 fills | 8,147 | $124.22 avg | $1.0M | Jun 4, 2026 |
| Robert B CarterDirector | Award | 1,142 | – | – | May 20, 2026 |
| Vicky B GreggDirector | Award | 1,142 | – | – | May 20, 2026 |
| Luis DiazDirector | Award | 1,142 | – | – | May 20, 2026 |
| Timothy L MainDirector | Award | 1,142 | – | – | May 20, 2026 |
| Timothy C WentworthDirector | Award | 1,142 | – | – | May 20, 2026 |
| Tracey DoiDirector | Award | 1,142 | – | – | May 20, 2026 |
| Timothy M RingDirector | Award | 1,142 | – | – | May 20, 2026 |
| Wright Iii LassiterDirector | Award | 1,142 | – | – | May 20, 2026 |
| Denise M MorrisonDirector | Award | 1,142 | – | – | May 20, 2026 |
| Gary M PfeifferDirector | Award | 1,142 | – | – | May 20, 2026 |
| Sam SamadExecutive Vice President & CFO | Award | 108 | $194.70 | $21K | Apr 20, 2026 |
| Vicky B GreggDirector | Award | 68 | $194.70 | $13K | Apr 20, 2026 |
| Patrick PlewmanSVP for Diagnostic Services | L | 49 | $194.70 | $9,540 | Apr 20, 2026 |
| Karthik KuppusamySVP, Clinical Solutions | L | 39 | $194.70 | $7,593 | Apr 20, 2026 |
| Mark E DelaneySVP & Chief Commercial Officer | L | 37 | $194.70 | $7,204 | Apr 20, 2026 |
| Robert B CarterDirector | L | 7 | $194.70 | $1,363 | Apr 20, 2026 |
| Wright Iii LassiterDirector | L | 6 | $194.70 | $1,168 | Apr 20, 2026 |
| Timothy C WentworthDirector | Award | 215 | – | – | Mar 9, 2026 |
| J. E. DavisCEO and President, Director | Award | 51,652 | $204.86 | $10.6M | Mar 4, 2026 |
| J. E. DavisCEO and President, Director | Tax withholding | 26,414 | $204.86 | $5.4M | Mar 4, 2026 |
| Sam SamadExecutive Vice President & CFO | Award | 13,947 | $204.86 | $2.9M | Mar 4, 2026 |
| Catherine T. DohertyEVP, Regional Businesses | Awardpre-set plan | 11,364 | $204.86 | $2.3M | Mar 4, 2026 |
| Sam SamadExecutive Vice President & CFO | Tax withholding | 7,720 | $204.86 | $1.6M | Mar 4, 2026 |
| Michael E PrevoznikSVP & General Counsel | Awardpre-set plan | 7,232 | $204.86 | $1.5M | Mar 4, 2026 |
| Karthik KuppusamySVP, Clinical Solutions | Award | 6,200 | $204.86 | $1.3M | Mar 4, 2026 |
| Catherine T. DohertyEVP, Regional Businesses | Tax withholdingpre-set plan | 5,806 | $204.86 | $1.2M | Mar 4, 2026 |
| Mark E DelaneySVP & Chief Commercial Officer | Award | 5,682 | $204.86 | $1.2M | Mar 4, 2026 |
| Patrick PlewmanSVP for Diagnostic Services | Awardpre-set plan | 5,682 | $204.86 | $1.2M | Mar 4, 2026 |
| Michael E PrevoznikSVP & General Counsel | Tax withholdingpre-set plan | 3,354 | $204.86 | $687K | Mar 4, 2026 |
| Patrick PlewmanSVP for Diagnostic Services | Tax withholdingpre-set plan | 2,827 | $204.86 | $579K | Mar 4, 2026 |
| Mark E DelaneySVP & Chief Commercial Officer | Tax withholding | 2,326 | $204.86 | $477K | Mar 4, 2026 |
| Michael J DeppeSVP, Corp. Controller & CAO | Award | 1,473 | $204.86 | $302K | Mar 4, 2026 |
| Michael J DeppeSVP, Corp. Controller & CAO | Tax withholding | 750 | $204.86 | $154K | Mar 4, 2026 |
| J. E. DavisCEO and President, Director | Tax withholdingpre-set plan | 2,968 | $204.86 | $608K | Mar 2, 2026 |
| Sam SamadExecutive Vice President & CFO | Tax withholding | 869 | $204.86 | $178K | Mar 2, 2026 |
| Catherine T. DohertyEVP, Regional Businesses | Tax withholdingpre-set plan | 648 | $204.86 | $133K | Mar 2, 2026 |
| Michael E PrevoznikSVP & General Counsel | Tax withholdingpre-set plan | 288 | $204.86 | $59K | Mar 2, 2026 |
| Patrick PlewmanSVP for Diagnostic Services | Tax withholdingpre-set plan | 230 | $204.86 | $47K | Mar 2, 2026 |
| Karthik KuppusamySVP, Clinical Solutions | Tax withholding | 205 | $204.86 | $42K | Mar 2, 2026 |
| Mark E DelaneySVP & Chief Commercial Officer | Tax withholding | 188 | $204.86 | $39K | Mar 2, 2026 |
| Michael J DeppeSVP, Corp. Controller & CAO | Tax withholding | 88 | $204.86 | $18K | Mar 2, 2026 |
Trades by members of Congress
4 members reported 2 buys and 6 sales since Jan 24, 2025. Amounts are legal ranges, not exact figures.
| Member | Trade | Amount | Traded | Reported | Owner |
|---|---|---|---|---|---|
| Carol D. Miller R | Sold | $15K–$50K | Mar 10, 2025 | Aug 13, 2026521 days later | Spouse |
| Julie Johnson D | Sold | $1,001–$15K | Oct 30, 2025 | Aug 5, 2026279 days later | Joint |
| Julie Johnson D | Bought | $1,001–$15K | Oct 30, 2025 | Aug 5, 2026279 days later | Joint |
| Julia Letlow R | Sold | $1,001–$15K | Jul 24, 2025 | Jan 13, 2026173 days later | Self |
| Julia Letlow R | Bought | $1,001–$15K | Apr 28, 2025 | Jan 13, 2026260 days later | Self |
| Julie Johnson D | Sold | $1,001–$15K | Nov 3, 2025 | Dec 11, 2025 | Joint |
| Carol D. Miller R | Sold | $1,001–$15K | Mar 10, 2025 | Apr 11, 2025 | Self |
| Gilbert Ray Cisneros, Jr. D | Sold some | $1,001–$15K | Jan 24, 2025 | Feb 11, 2025 | Self |
Latest SEC filings
- Insider plans to sell 144 · Oct 26, 2026
- Quarterly report 10-Q · Oct 23, 2026
- News filing: Other news 8-K · Oct 22, 2026
- News filing: Quarterly results 8-K · Oct 22, 2026
- News filing: Executive or board change 8-K · Oct 6, 2026
- Insider plans to sell 144 · Sep 1, 2026
- Insider plans to sell 144 · Aug 28, 2026
- Insider plans to sell 144 · Jul 28, 2026
- Quarterly report 10-Q · Jul 23, 2026
- News filing: Quarterly results 8-K · Jul 23, 2026
- Insider plans to sell 144 · Jun 4, 2026
- Insider plans to sell 144 · Jun 1, 2026
- News filing: Shareholder vote results 8-K · May 21, 2026
- News filing: Signed a major agreement 8-K · May 8, 2026
- News filing: Other news 8-K · May 1, 2026
- Quarterly report 10-Q · Apr 22, 2026
- News filing: Quarterly results 8-K · Apr 21, 2026
- Shareholder meeting proxy DEF 14A · Apr 6, 2026
- News filing: Executive or board change, Public announcement (Reg FD) 8-K · Mar 12, 2026
- Insider plans to sell 144 · Mar 5, 2026
- Insider plans to sell 144 · Mar 5, 2026
- Insider plans to sell 144 · Mar 5, 2026
- Insider plans to sell 144 · Mar 3, 2026
- Insider plans to sell 144 · Mar 3, 2026
- Insider plans to sell 144 · Mar 3, 2026
About Quest Diagnostics Inc.
Business description
- Industry
- Services-Medical Laboratories
- Sector
- Industrial Applications and Services
- Headquarters
- Secaucus, NJ
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Exchange
- NYSE
- Filer size
- Large accelerated filer
- Formerly
- CORNING CLINICAL LABORATORIES INC
- SEC company number (CIK)
- 1022079
Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.